Core Points - Evaxion A/S, a clinical-stage TechBio company, will provide a business update and report its Q3 2025 financial results on November 6, 2025 [1] - The company's Executive Management will host a conference call and webcast on the same day at 14:30 CET/08:30 EST, which is open to the public [2] - Evaxion specializes in developing AI-Immunology™ powered vaccines, focusing on immunotherapies for cancer, bacterial diseases, and viral infections [4] Company Overview - Evaxion A/S utilizes its proprietary AI platform, AI-Immunology™, to decode the human immune system and develop novel immunotherapies [4] - The company has a clinical-stage oncology pipeline of personalized vaccines and a preclinical pipeline targeting bacterial and viral diseases with high unmet medical needs [4] - Evaxion aims to transform patients' lives by providing innovative and targeted treatment options [4]

Core Insights - Evaxion A/S has finalized an agreement with the European Investment Bank (EIB) to convert €3.5 million of its €7 million loan into equity, enhancing its capital structure and financial flexibility [1][2][6] Group 1: Financial Impact - The conversion involves EIB purchasing ordinary Evaxion warrants at a price of $4.87, which represents a premium of 89% over the share price at market close yesterday [2][6] - This agreement immediately increases Evaxion's equity by $4.1 million (€3.5 million), while also substantially reducing overall liabilities and simplifying the balance sheet [2][6] Group 2: Management Commentary - The CFO of Evaxion, Thomas F. Schmidt, expressed satisfaction with the favorable terms of the agreement, highlighting its importance for cash flow and financial management [3]